Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 629-636, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aguilera, R.
Right arrow Articles by Catlin, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aguilera, R.
Right arrow Articles by Catlin, D. H.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:629-636.)
© 2002 American Association for Clinical Chemistry, Inc.

Detection of Epitestosterone Doping by Isotope Ratio Mass Spectrometry

Rodrigo Aguilera1, Caroline K. Hatton1 and Don H. Catlin1,2a

1 UCLA Olympic Analytical Laboratory, Department of Molecular and Medical Pharmacology, and
2 Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90025-6106.

aAddress correspondence to this author at: UCLA Olympic Analytical Laboratory, 2122 Granville Ave., Los Angeles, CA 90025. Fax 310-206-9077; e-mail dcatlin{at}ucla.edu.

Background: Epitestosterone is prohibited by sport authorities because its administration will lower the urinary testosterone/epitestosterone ratio, a marker of testosterone administration. A definitive method for detecting epitestosterone administration is needed.

Methods: We developed a gas chromatography-combustion-isotope ratio mass spectrometry method for measuring the {delta}13C values for urinary epitestosterone. Sample preparation included deconjugation with ß-glucuronidase, solid-phase extraction, and semipreparative HPLC. Epitestosterone concentrations were determined by gas chromatography-mass spectrometry for urines obtained from a control group of 456 healthy males. Epitestosterone {delta}13C values were determined for 43 control urines with epitestosterone concentrations >=40 µg/L (139 nmol/L) and 10 athletes’ urines with epitestosterone concentrations >=180 µg/L (624 nmol/L), respectively.

Results: The log epitestosterone concentration distribution was gaussian [mean, 3.30; SD, 0.706; geometric mean, 27.0 µg/L (93.6 nmol/L)]. The {delta}13C values for four synthetic epitestosterones were low (less than or equal to -30.3{per thousand}) and differed significantly (P <0.0001). The SDs of between-assay precision studies were low (<=0.73{per thousand}). The mean {delta}13C values for urine samples obtained from 43 healthy males was -23.8{per thousand} (SD, 0.93{per thousand}). Nine of 10 athletes’ urine samples with epitestosterone concentrations >180 µg/L (624 nmol/L) had {delta}13C values within ± 3 SD of the control group. The {delta}13C value of epitestosterone in one sample was -32.6{per thousand} (z-score, 9.4), suggesting that epitestosterone was administered. In addition, the likelihood of simultaneous testosterone administration was supported by low {delta}13C values for androsterone and etiocholanolone.

Conclusions: Determining {delta}13C values for urinary epitestosterone is useful for detecting cases of epitestosterone administration because the mean {delta}13C values for a control group is high (-23.8{per thousand}) compared with the {delta}13C values for synthetic epitestosterones.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
B. Starcevic and A. W. Butch
Genetic Variations in UDP-Glucuronosyl Transferase 2B17: Implications for Testosterone Excretion Profiling and Doping Control Programs
Clin. Chem., December 1, 2008; 54(12): 1945 - 1947.
[Full Text] [PDF]

Home page
 Br. J. Sports. Med.Home page
C Saudan, N Baume, N Robinson, L Avois, P Mangin, and M Saugy
Testosterone and doping control
Br. J. Sports Med., July 1, 2006; 40(suppl_1): i21 - i24.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.